SONOMA PHARMACEUTICALS INC

SONOMA PHARMACEUTICALS INC

Acción · US83558L2043 · SNOA · A2PMPH (XNCM)
Resumen
Análisis impulsado por IA
Análisis fundamental
Descubre lo que realmente dicen los números — antes que el mercado
Analizar ahora
Sentimiento de noticias
¿Las noticias de hoy son una señal de compra o una alerta?
Analizar ahora
Comprar / Mantener / Vender
¿Comprar, mantener o vender? Obtén el veredicto de la IA ahora.
Analizar ahora
Evaluación de riesgos
Descubre riesgos ocultos antes de que afecten a tu cartera.
Analizar ahora
Valor justo
¿Esta acción está barata, correctamente valorada o sobrevalorada?
Analizar ahora
Últimos análisis de IA sobre SONOMA PHARMACEUTICALS INC
Resumen de la Calificación de Analistas
gauge-img
Comprar
Compra Fuerte
Comprar
Mantener
Vender
Venta Fuerte
0
1
1
0
0
Sin cotización
29.04.2026 18:44
Cotizaciones actuales de SONOMA PHARMACEUTICALS INC
BolsaTickerMonedaÚltima operaciónPrecioVariación diaria
IEXG: IEX
IEX
SNOA
USD
29.04.2026 18:44
1,06 USD
0,01 USD
+1,44 %
XNAS: NASDAQ
NASDAQ
SNOA
USD
29.04.2026 18:41
1,05 USD
0,01 USD
+0,96 %
Flotación y Liquidez de las Acciones
Flotación Libre 98,79 %
Acciones en Flotación 1,72 M
Acciones en Circulación 1,74 M
Perfil de la empresa para SONOMA PHARMACEUTICALS INC Acción
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a HOCl-based topical prescription product indicated to promote efficient healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens, as well as antibiotic-resistant strains that slow the natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Ocucyn eyelid and eyelash cleanser; Gramaderm for the treatment of topical mild to moderate acne; Nanocyn, a hospital-grade disinfectant; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.

Datos de la empresa

Nombre SONOMA PHARMACEUTICALS INC
Empresa Sonoma Pharmaceuticals, Inc.
Símbolo SNOA
Sitio web https://www.sonomapharma.com
Mercado principal XNCM NASDAQ CAPITAL MARKET
WKN A2PMPH
ISIN US83558L2043
Tipo de valor Acción
Sector Healthcare
Industria Drug Manufacturers - Specialty & Generic
CEO Amy M. Trombly
País Estados Unidos de América
Moneda USD
Empleados 0,0 T
Dirección 645 Molly Lane, 30189 Woodstock
Fecha de OPV 2007-01-25

Splits de acciones

Fecha Split
30.08.2024 1:20
20.06.2019 1:9
27.06.2016 1:5
01.04.2013 1:7

Cambios de identificador

Fecha De A
19.12.2016 OCLS SNOA

Símbolos de cotización

Nombre Símbolo
Frankfurt O8Z3.F
NASDAQ SNOA
Otras acciones
Los inversores que tienen SONOMA PHARMACEUTICALS INC también tienen las siguientes acciones en su cartera:
APT PIPELINES 15/22 MTN
APT PIPELINES 15/22 MTN Bono
BLACKST. HFC 21/28 REGS
BLACKST. HFC 21/28 REGS Bono